A Phase Ia Clinical Study of QLF31907 Injection in Patients With Advanced Malignant Tumors
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the safety and tolerability of QLF31907 injection, to
identify the maximum tolerated dose (MTD) and dose-limiting toxicity(DLT), and determine the
recommended phase Ib dose(RPIbD) and recommended phase II dose (RP2D)in patients with
advanced malignant tumors.